|
|
| (27 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| − | {{pnc}} | + | {{pnc}}__NOTOC__ |
| | | | |
| − | '''Antibody-dependent enhancement''' | + | {{ft|I}} |
| | + | *'''[[Antibody-dependent enhancement ]]''' |
| | + | *'''[[Herd immunity ]]''' |
| | + | *'''[[Neutralizing antibodies ]]''' |
| | + | *'''[[Innate immunology ]]''' |
| | + | *'''[[Integrative work ]]''' ''reviews, intertopic'' |
| | + | *'''[[Cov2 modulates the immune system ]]''' |
| | + | *'''[[Immune cell subpopulations ]]''' |
| | + | *'''[[T cell exhaustion ]]''' |
| | + | *'''[[NK cells ]]''' |
| | | | |
| − | {{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}}
| + | *'''[[MDSC myeloid-derived suppressor cells]] |
| − | {{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}}
| + | *'''[[Antiviral immune response ]]''' |
| − | {{ttp|p=31826992|t=2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |pdf=|usr=}}''antibodies target one serotype of viruses but only subneutralize another, leading to antibody-dependend enhancement of the latter viruses.''
| + | *'''[[Antiviral mediators ]]''' |
| − | {{ttp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}} ade
| + | *'''[[Immunopathology ]]''' |
| − | {{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
| + | *'''[[Secondary autoimmunity ]]''' |
| − | {{tp|p=32303697|t=ä. Will we see protection or reinfection in COVID-19?|pdf=|usr=}}
| + | *'''[[Thymus, Immunosenescence ]]''' |
| − | {{tp|p=32438257|t=2020. SARS-CoV-2 and enhancing antibodies |pdf=|usr=}}
| + | *'''[[Eosinophils ]]''' |
| − | {{ttp|p=32408068|t=2020. What about the original antigenic sin of the humans versus SARS-CoV-2?|pdf=|usr=}}''the term «original antigenic sin» (OAS) was coined by T. Francis Jr at the Michigan University in the late 1950s to describe patterns of antibody response to influenza vaccination...''
| + | *'''[[Microbiome ]]''' |
| − | | + | *'''[[Pneumococcal synergism]]''' -new- |
| − | '''Innate sensing of infection''' | + | *'''[[Bio-misc ]]''' ''on topic biology papers which cannot be indexed by title'' |
| − | {{ttp|p=32291557|t=ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |pdf=|usr=}}
| + | *'''[[Hematology ]]''' |
| − | {{tp|p=32198201|t=2020. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors |pdf=|usr=}}
| + | *'''[[Cytokine_storm,_hemophagocytic_lymphohistiocytosis,_macrophage_activation_syndrome|Cytokine storm ]]''' |
| − | {{tp|p=32374430|t=2020. DC/L-SIGNs of Hope in the COVID-19 Pandemic |pdf=|usr=}}
| + | *'''[[Candidate_Compounds_Covid19 |Immunopharmacology ]]''' |
| − | {{tp|p=32361001|t=ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes |pdf=|usr=}}
| + | *'''[[Diagnosis_(Laboratory) |Clinical Laboratory Dx]]''' |
| − | {{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}}
| + | |
| − | {{ttp|p=32407669|t=ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''nk cells''' | + | |
| − | {{tp|p=32382127|t=ä. NKG2A and COVID-19: another brick in the wall |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''integrative work''' | + | |
| − | *[https://www.cell.com/action/showPdf?pii=S1074-7613%2820%2930183-7 rev. on covid immunology] | + | |
| − | {{tp|p=32205856|t=2020. COVID-19 infection: the perspectives on immune responses |pdf=|usr=}}
| + | |
| − | {{tp|p=32359396|t=ä. A Dynamic Immune Response Shapes COVID-19 Progression |pdf=|usr=}}
| + | |
| − | {{tp|p=C7064018|t=ä. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses |pdf=|usr=}}
| + | |
| − | {{ttp|p=C7200337|t=ä. Immunology of COVID-19: current state of the science |pdf=|usr=}}
| + | |
| − | {{tp|p=32505227|t=2020. Immunology of COVID-19: Current State of the Science.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | '''covid modulates the immune system''' | + | |
| − | {{tp|p=32364527|t=2020. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32172672|t=2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses |pdf=|usr=}}
| + | |
| − | {{tp|p=32315725|t=ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{ttp|p=32355328|t=ä. Impaired interferon signature in severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32375560|t=2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study |pdf=|usr=}}
| + | |
| − | {{tp|p=32376308|t=ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}}
| + | |
| − | {{ttp|p=32236983|t=2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{ttp|p=32286536|t=ä. Coronaviruses hijack the complement system |pdf=|usr=}}''host complement activator MASP2 as a target of the N protein of all three viruses''
| + | |
| − | | + | |
| − | '''mediators''' | + | |
| − | {{tp|p=32360285|t=ä. Type I IFN immunoprofiling in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32376393|t=ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms |pdf=|usr=}}
| + | |
| − | {{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}}
| + | |
| − | {{tp|p=30715745|t=2019. (+)Th17 serum cytokines in relation to laboratory?confirmed respiratory viral infection: A pilot study |pdf=|usr=}}
| + | |
| − | {{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | '''plasmacytoid dendritic cells''' | + | |
| − | {{tp|p=32298486|t=2020. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19) |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''immune cell subpopulations''' | + | |
| − | {{tp|p=32282871|t=ä. Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32325421|t=2020. Increased expression of CD8 marker on T-cells in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
| + | |
| − | {{tp|p=32346099|t=ä. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32228226|t=2020. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32196410|t=2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection?a review of immune changes in patients with viral pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32333914|t=ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia |pdf=|usr=}}
| + | |
| − | {{tp|p=32344320|t=ä. The clinical course and its correlated immune status in COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32325129|t=ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32283159|t=ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32227123|t=ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32343510|t=2020. COVID-19: are T lymphocytes simply watching?|pdf=|usr=}}
| + | |
| − | {{tp|p=32379887|t=ä. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32297671|t=2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32352397|t=2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study |pdf=|usr=}}
| + | |
| − | {{tp|p=32379199|t=2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes |pdf=|usr=}}
| + | |
| − | {{tp|p=32296069|t=2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{tp|p=32297828|t=2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32370466|t=2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32114745|t=2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
| + | |
| − | {{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32376308|t=2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | '''t cell exhaustion''' | + | |
| − | {{tp|p=32249845|t=ä. Fighting COVID-19 exhausts T cells |pdf=|usr=}}
| + | |
| − | | + | |
| − | {{ttp|p=32203188|t=ä. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32203186|t=ä. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32203188|t=2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{ttp|p=32203186|t=2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | '''immunopathology''' | + | |
| − | {{tp|p=32371101|t=ä. The correlation between SARS-CoV-2 infection and rheumatic disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32205186|t=2020. COVID-19 infection and rheumatoid arthritis: Faraway, so close!|pdf=|usr=}}
| + | |
| − | {{tp|p=32308263|t=2020. CoViD-19 Immunopathology and Immunotherapy |pdf=|usr=}}
| + | |
| − | {{tp|p=32320677|t=ä. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure |pdf=|usr=}}
| + | |
| − | {{tp|p=32161940|t=ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32282863|t=ä. Molecular immune pathogenesis and diagnosis of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32321823|t=2020. COVID-19: an Immunopathological View |pdf=|usr=}}
| + | |
| − | {{tp|p=32273594|t=ä. COVID-19: immunopathology and its implications for therapy |pdf=|usr=}}
| + | |
| − | {{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}}
| + | |
| − | {{ttp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''antiviral immune response'''
| + | |
| − | {{tp|p=32280952|t=ä. Good IgA bad IgG in SARS-CoV-2 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32353870|t=2020. The many faces of the anti-COVID immune response |pdf=|usr=}}
| + | |
| − | {{tp|p=32358956|t=ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=31981224|t=2020. Coronavirus infections and immune responses |pdf=|usr=}}
| + | |
| − | {{tp|p=32198005|t=2020. A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic |pdf=|usr=}}
| + | |
| − | {{tp|p=32284614|t=ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32355329|t=ä. SARS-CoV-2-reactive T cells in patients and healthy donors |pdf=|usr=}}
| + | |
| − | {{tp|p=32346091|t=ä. Neutralizing antibody response in mild COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32356908|t=2020. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis |pdf=|usr=}}
| + | |
| − | {{ttp|p=32343415|t=2020. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32330332|t=2020. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32267987|t=2020. Immune responses and pathogenesis of SARS?CoV?2 during an outbreak in Iran: Comparison with SARS and MERS |pdf=|usr=}}
| + | |
| − | {{tp|p=32348715|t=2020. B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32382126|t=ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32200654|t=2020. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''secondary autoimmunity''' | + | |
| − | {{tp|p=32292901|t=2020. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity |pdf=|usr=}}
| + | |
| − | {{tp|p=32220633|t=2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?|pdf=|usr=}}
| + | |
| − | {{tp|p=32315487|t=2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19 |pdf=|usr=}}
| + | |
| − | {{ttp|p=32314313|t=2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?|pdf=|usr=}}
| + | |
| − | {{tp|p=32389543|t=ä. COVID-19 and molecular mimicry: The Columbus? egg?|pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | | + | |
| − | '''Thymus''' | + | |
| − | {{tp|p=32340873|t=ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype |pdf=|usr=}}
| + | |
| − | {{tp|p=32317217|t=ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''Eosinopenia, Eosinophilia''' | + | |
| − | {{tp|p=32368728|t=ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study |pdf=|usr=}}
| + | |
| − | {{tp|p=32344056|t=ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination |pdf=|usr=}}
| + | |
| − | {{tp|p=32369190|t=2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series |pdf=|usr=}}
| + | |
| − | {{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| + | |
| − | | + | |
| − | '''Immunogenetics''' | + | |
| − | {{tp|p=32303592|t=2020. Human leukocyte antigen susceptibility map for SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32343152|t=2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | ===007===
| + | |
| − | | + | |
| − | {{tp|p=32454497|t=2020. COVID-19 and Nasal Cytobrush Cytology.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437316|t=2020. Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412897|t=2020. Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19, Japan.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476607|t=2020. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475230|t=2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471334|t=2020. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496247|t=2020. Genome analysis of SARS-CoV-2 isolates occurring in India: Present scenario.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393680|t=2020. Incomplete Kawasaki Disease in a Child with Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423095|t=2020. The Expression and Polymorphism of Entry Machinery for COVID-19 in Human: Juxtaposing Population Groups, Gender, and Different Tissues.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397174|t=2020. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463803|t=2020. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32459663|t=2020. COVID-19, microangiopathy, hemostatic activation, and complement.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32217834|t=2020. SARS-CoV-2: a storm is raging.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32486469|t=2020. COVID-19 Related Coagulopathy: A Distinct Entity?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32466577|t=2020. Early Phylogenetic Diversification of SARS-CoV-2: Determination of Variants and the Effect on Epidemiology, Immunology, and Diagnostics.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32422996|t=2020. Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32403217|t=2020. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492165|t=2020. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427582|t=2020. Clinical and pathological investigation of severe COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501293|t=2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492292|t=2020. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32484232|t=2020. Radiologisk och histologisk bild for en okad forstaelse vid covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475810|t=2020. The role of biomarkers in diagnosis of COVID-19 - A systematic review.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32471829|t=2020. Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-Related Viruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512290|t=2020. Expression of angiotensin-converting enzyme 2 and proteases in COVID-19 patients: A potential role of cellular FURIN in the pathogenesis of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512491|t=2020. COVID-19-related complications and decompression illness share main features.: Could the SARS-CoV2-related complications rely on blood foaming?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32499358|t=2020. Complete Genome Sequence of a SARS-CoV-2 Strain Isolated in Northern Germany.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32401000|t=2020. First ultrastructural autoptic findings of SARS-Cov-2 in olfactory pathways and brainstem.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32483236|t=2020. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512569|t=2020. COVID-19 Attacks the Kidney: Ultrastructural Evidence for the Presence of Virus in the Glomerular Epithelium.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418306|t=2020. Comment on Matricardi PM et al: The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462467|t=2020. Covid-19 and Kawasaki Disease: A Glimpse at the Past for a Predictable Future.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397896|t=2020. Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437232|t=2020. Virus-induced genetics revealed by multidimensional precision medicine transcriptional workflow applicable to COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469225|t=2020. COVID-19 and the immune system.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511245|t=2020. A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437478|t=2020. Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32449333|t=2020. Ability of the immune system to fight viruses highlighted by cytometry and TCR clonotype assessments: lessons taken prior to COVID-19 virus pandemic outbreak.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32439706|t=2020. Reply to Sanchez-Pacheco et al., Chookajorn, and Mavian et al.: Explaining phylogenetic network analysis of SARS-CoV-2 genomes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32436320|t=2020. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32428139|t=2020. Hematological changes in Covid-19 infections.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32404436|t=2020. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32507360|t=2020. Delirium, sleep, COVID-19 and melatonin.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32436629|t=2020. High COVID-19 virus replication rates, the creation of antigen-antibody immune complexes and indirect haemagglutination resulting in thrombosis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32507543|t=2020. Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32421281|t=2020. Is there relationship between SARS-CoV 2 and the complement C3 and C4?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496734|t=2020. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438622|t=2020. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423059|t=2020. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32422894|t=2020. A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32482591|t=2020. Swine enteric alphacoronavirus (swine acute diarrhea syndrome coronavirus): An update three years after its discovery.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503352|t=2020. Genomic Sequencing and Analysis of Eight Camel-Derived Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Isolates in Saudi Arabia.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485101|t=2020. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420946|t=2020. COVID-19 and food allergy in children.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32430094|t=2020. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32451547|t=2020. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423917|t=2020. COVID-19 as an Acute Inflammatory Disease.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463092|t=2020. Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441749|t=2020. COVID-19 Associated Pediatric Multi-System Inflammatory Syndrome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32478523|t=2020. Comparing the Binding Interactions in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32461321|t=2020. Porcine epidemic diarrhea virus deficient in RNA cap guanine-N-7 methylation is attenuated and induces higher type I and III interferon responses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32461317|t=2020. Porcine Deltacoronavirus nsp5 Cleaves DCP1A to Decrease Its Antiviral Ability.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32434888|t=2020. Replication of SARS-CoV-2 in human respiratory epithelium.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32404529|t=2020. Comparison of SARS-CoV-2 spike protein binding to ACE2 receptors from human, pets, farm animals, and putative intermediate hosts.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32391855|t=2020. COVID-19 and Postinfection Immunity: Limited Evidence, Many Remaining Questions.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511692|t=2020. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511676|t=2020. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511667|t=2020. SARS-CoV-2-Related Inflammatory Multisystem Syndrome in Children: Different or Shared Etiology and Pathophysiology as Kawasaki Disease?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32424314|t=2020. SARS-CoV-2 causes COVID-19-like disease in cynomolgus macaques.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504757|t=2020. Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504754|t=2020. Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512289|t=2020. Neutralizing antibodies mediate virus-immune pathology of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505911|t=2020. Antibiotic consumption may be linked to exaggeration of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485313|t=2020. MDA5 should be detected in severe COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506536|t=2020. Emerging viral mutants in Australia suggest RNA recombination event in the SARS-CoV-2 genome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490726|t=2020. Thromboinflammatory response in SARS-CoV-2 sepsis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407057|t=2020. Peripheral lymphocyte subset monitoring in COVID19 patients: a prospective Italian real-life case series.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32407507|t=2020. Genomic epidemiology, evolution, and transmission dynamics of porcine deltacoronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437597|t=2020. Covid-19, Angiogenesis, and ARDS Endotypes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437596|t=2020. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504046|t=2020. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32405028|t=2020. Infection of bat and human intestinal organoids by SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32398875|t=2020. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32454513|t=2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32454512|t=2020. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32438371|t=2020. Structure of replicating SARS-CoV-2 polymerase.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32408338|t=2020. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32396922|t=2020. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469258|t=2020. Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423291|t=2020. Association Between COVID-19 and Kawasaki Disease: Vigilance Required From Otolaryngologists.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510562|t=2020. Long-term and herd immunity against SARS-CoV-2: implications from current and past knowledge.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32467454|t=2020. Covid-19 and Kawasaki Disease: An Etiology or Coincidental Infection?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492695|t=2020. Does the newly observed inflammatory syndrome in children demonstrate a link between uncontrolled neutrophil extracellular traps formation and COVID-19?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32439816|t=2020. SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32456506|t=2020. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397915|t=2020. Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503918|t=2020. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32401447|t=2020. Quels liens entre le SARS-CoV-2 et la maladie de Kawasaki ?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32348061|t=2020. COVID-19, une maladie endotheliale ?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32502331|t=2020. Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32467379|t=2020. The search for a COVID-19 animal model.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32299928|t=2020. From mice to monkeys, animals studied for coronavirus answers.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32433216|t=2020. Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32482825|t=2020. Testing animals for SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490723|t=2020. Development of a TaqMan-probe-based multiplex real-time PCR for the simultaneous detection of emerging and reemerging swine coronaviruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496715|t=2020. [Etiology of epidemic outbreaks COVID-19 on Wuhan, Hubei province, Chinese People Republic associated with 2019-nCoV (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, Subgenus Sarbecovirus): lessons of SARS-CoV outbreak.]|pdf=|usr=007}}
| + | |
| − | {{tp|p=32391668|t=2020. [Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32392945|t=2020. [Comparison of pathological changes and pathogenic mechanisms caused by H1N1 influenza virus, highly pathogenic H5N1 avian influenza virus, SARS-CoV, MERS-CoV and 2019-nCoV].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32213267|t=2020. [Interpretation of pathological changes for "Guidelines for the Diagnosis and Treatment of COVID-19 by the National Health Commission (Trial Version 7) "].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32486534|t=2020. [Pathological changes of fatal coronavirus disease 2019 (COVID-19) in the lungs: report of 10 cases by postmortem needle autopsy].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32241072|t=2020. [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019].|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455515|t=2020. [Clinical feature changes of a COVID-19 patient from mild to critical condition and cardiopulmonary pathological results].|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32444414|t=2020. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455617|t=2020. Novel Dynamic Structures of 2019-nCoV with Nonlocal Operator via Powerful Computational Technique.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418947|t=2020. Does immune privilege result in recovered patients testing positive for COVID-19 again?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493739|t=2020. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32467125|t=2020. Morphology of COVID-19-affected cells in peripheral blood film.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453863|t=2020. COVID-19 and ABO blood group: another viewpoint.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32453859|t=2020. Clinical significance of blue-green neutrophil and monocyte cytoplasmic inclusions in SARS-CoV-2 positive critically ill patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32433784|t=2020. High-fluorescent lymphocytes are increased in patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420613|t=2020. Atypical lymphocytes in peripheral blood of patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420610|t=2020. Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462701|t=2020. Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512133|t=2020. Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458561|t=2020. Lymphopenia in COVID-19: Therapeutic opportunities.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32443810|t=2020. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32498376|t=2020. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393592|t=2020. Cytokine storm and the prospects for immunotherapy with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493734|t=2020. New spectrum of COVID-19 manifestations in children: Kawasaki-like syndrome and hyperinflammatory response.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511972|t=2020. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32511971|t=2020. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32508038|t=2020. Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32508022|t=2020. Acute lung injury in patients with COVID-19 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490934|t=2020. Ultrasound-guided minimally invasive autopsies: A protocol for the study of pulmonary and systemic involvement of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503659|t=2020. Body temperature correlates with mortality in COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503382|t=2020. Biomarkers associated with COVID-19 disease progression.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32452762|t=2020. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32428990|t=2020. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32384045|t=2020. Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32459984|t=2020. SARS-CoV-2 Phylogenetic Analysis, Lazio Region, Italy, February-March 2020.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32507410|t=2020. The influenza virus, SARS-CoV-2, and the airways: Clarification for the otorhinolaryngologist.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32507608|t=2020. Hepatic consequences of COVID-19 infection. Lapping or biting?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32427393|t=2020. Telomeres and COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32428379|t=2020. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32505742|t=2020. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children (MIS-C) that is related to COVID-19: a single center experience of 44 cases.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32443177|t=2020. Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32424945|t=2020. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460357|t=2020. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512089|t=2020. Corona virus versus existence of human on the earth: A computational and biophysical approach.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470223|t=2020. COVID-19: Structural Predictions of Viral Success.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441844|t=2020. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32512386|t=2020. Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32410502|t=2020. First comprehensive computational analysis of functional consequences of TMPRSS2 SNPs in susceptibility to SARS-CoV-2 among different populations.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32397951|t=2020. The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437018|t=2020. TMPRSS2: Potential Biomarker for COVID-19 Outcomes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32455505|t=2020. Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32508068|t=2020. Defining Association between COVID-19 and the Multisystem Inflammatory Syndrome in Children through the Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470153|t=2020. Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470148|t=2020. Serum KL-6 concentrations as a novel biomarker of severe COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462705|t=2020. Clinical features, isolation, and complete genome sequence of severe acute respiratory syndrome coronavirus 2 from the first two patients in Vietnam.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32458459|t=2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32479682|t=2020. Preeclampsia-like syndrome induced by severe COVID-19: a prospective observational study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32423901|t=2020. How covid-19 is accelerating the threat of antimicrobial resistance.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32414749|t=2020. Covid-19: Cases of inflammatory syndrome in children surge after urgent alert.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493704|t=2020. Pediatric inflammatory syndrome temporally related to covid-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420607|t=2020. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32495372|t=2020. Terminal complement inhibition dampens the inflammation during COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32497257|t=2020. A lesson from a saboteur: high molecular weight kininogen (HMWK) impact in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32484220|t=2020. Discovery of G-quadruplex-forming sequences in SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32444466|t=2020. The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412400|t=2020. Covid-19 and Kawasaki syndrome: should we really be surprised?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420587|t=2020. COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32467617|t=2020. Serum IgA, IgM, and IgG responses in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32467616|t=2020. More bricks in the wall against SARS-CoV-2 infection: involvement of gamma9delta2 T cells.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32484450|t=2020. Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19).|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504637|t=2020. Elevated monocyte distribution width in COVID-19 patients: The contribution of the novel sepsis indicator.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32463434|t=2020. Metatranscriptomic Characterization of COVID-19 Identified A Host Transcriptional Classifier Associated With Immune Signaling.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32445579|t=2020. Prognostic value of C-reactive protein in patients with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32497196|t=2020. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32497191|t=2020. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32390402|t=2020. SARS-CoV-2 and Eosinophilia.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32414743|t=2020. Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506725|t=2020. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32488957|t=2020. Procedures for Flow Cytometry-Based Sorting of Unfixed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Cells and Other Infectious Agents.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32430459|t=2020. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418550|t=2020. Are Iranian Sulfur Mustard Gas-Exposed Survivors More Vulnerable to SARS-CoV-2? Some Similarity in Their Pathogenesis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501877|t=2020. Kinetic patterns of liver enzyme elevation with COVID-19 in the USA.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460534|t=2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412405|t=2020. Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32460624|t=2020. The amount of cytokine-release defines different shades of Sars-Cov2 infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472763|t=2020. Comparative analysis of Coronaviridae nucleocapsid and surface glycoprotein sequences.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32393819|t=2020. COVID-19 outcomes and the human genome.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32475052|t=2020. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32404331|t=2020. COVID-19 and Kawasaki Disease: Finding the Signal in the Noise.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32426999|t=2020. Gnotobiotic Rats Reveal That Gut Microbiota Regulates Colonic mRNA of Ace2, the Receptor for SARS-CoV-2 Infectivity.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503824|t=2020. Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503822|t=2020. Human Gene Sequences in SARS-CoV-2 and Other Viruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32503821|t=2020. SARS-CoV-2 orf1b Gene Sequence in the NTNG1 Gene on Human Chromosome 1.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474554|t=2020. Mapping the genomic landscape & diversity of COVID-19 based on >3950 clinical isolates of SARS-CoV-2: Likely origin & transmission dynamics of isolates sequenced in India.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474553|t=2020. Analysis of RNA sequences of 3636 SARS-CoV-2 collected from 55 countries reveals selective sweep of one virus type.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32462354|t=2020. Multisystem Inflammatory Syndrome with Features of Atypical Kawasaki Disease during COVID-19 Pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32485332|t=2020. SARS-CoV-2 Molecular and Phylogenetic analysis in COVID-19 patients: A preliminary report from Iran.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468151|t=2020. The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32468052|t=2020. Pancancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARSCoV2 infection leading to COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32456409|t=2020. A theory on SARS-COV-2 susceptibility: reduced TLR7-activity as a mechanistic link between men, obese and elderly.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32476380|t=2020. SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32490733|t=2020. Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32434769|t=2020. Viropathic multinuclear syncytial giant cells in bronchial fluid from a patient with COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32401043|t=2020. Conserved High Free Energy Sites in Human Coronavirus Spike Glycoprotein Backbones.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493812|t=2020. Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32474608|t=2020. Decreased B cells on admission was associated with prolonged viral RNA shedding from respiratory tract in Coronavirus Disease 2019: a case control study.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32433742|t=2020. Extended ORF8 Gene Region Is Valuable in the Epidemiological Investigation of SARS-similar Coronavirus.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506640|t=2020. Viral Infections and Their Relationship with Catastrophic Antiphospholipid Syndrome: A Possible Pathogenic Mechanism of Severe COVID-19 Thrombotic Complications.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472706|t=2020. The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470151|t=2020. The perplexing question of trained immunity versus adaptive memory in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32497323|t=2020. Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS-CoV-2) Infection.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32497295|t=2020. Comment on "Genetic variants and source of introduction of SARS-CoV-2 in South America".|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492206|t=2020. Understanding the possible origin and genotyping of first Bangladeshi SARS-CoV-2 strain.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492203|t=2020. Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in Lung cancer.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492196|t=2020. High-Coverage SARS-CoV-2 Genome Sequences Acquired by Target Capture Sequencing.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492195|t=2020. Functional prediction and frequency of coding variants in human ACE2 at binding sites with SARS-CoV-2 spike protein on different populations.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32492183|t=2020. Evidence for mutations in SARS-CoV-2 Italian isolates potentially affecting virus transmission.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32478897|t=2020. Conditional cell reprogramming for modeling host-virus interactions and human viral diseases.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32501810|t=2020. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32484453|t=2020. Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32413176|t=2020. The emergence of methemoglobinemia amidst the COVID-19 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510973|t=2020. Decoding SARS-CoV-2 Hijacking of Host Mitochondria in Pathogenesis of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32469255|t=2020. SARS-CoV-2 perturbs the Renin-Angiotensin System and energy metabolism.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32501731|t=2020. Cholesterol: A new game player accelerating endothelial injuries caused by SARS-CoV-2?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32493030|t=2020. Thoughts on the alveolar phase of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32504123|t=2020. COVID-19 research: toxicological input urgently needed!|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420944|t=2020. The impact of MicroRNAs (miRNAs) on the genotype of coronaviruses.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32420938|t=2020. What happens to people's lungs when they get coronavirus disease 2019?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32506059|t=2020. Detection of Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage Fluid of COVID-19 Patients: Is Perls Stain a Potential Indicator of Oxidative Alveolar Damage?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32496587|t=2020. Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32451533|t=2020. Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441303|t=2020. Placental Pathology in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32472588|t=2020. Increased sFLT1/PlGF ratio in COVID-19: a novel link to Angiotensin II-mediated endothelial dysfunction.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32491212|t=2020. Circulating endothelial cells in COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32479159|t=2020. Related molecular mechanisms of COVID-19, hypertension, and diabetes.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32437622|t=2020. Complement Activation During Critical Illness: Current Findings and an Outlook in the Era of COVID-19.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32432483|t=2020. Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32412787|t=2020. Bronchoscopy in COVID-19 Patients with Invasive Mechanical Ventilation: A Center Experience.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32410724|t=2020. The Lungs before and after COVID-19 Pneumonia.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32422081|t=2020. Autopsy Report with Clinical Pathological Correlation.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32510978|t=2020. Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis?|pdf=|usr=007}}
| + | |
| − | {{tp|p=32470119|t=2020. Coronavirus3D: 3D structural visualization of COVID-19 genomic divergence.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32418446|t=2020. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32386190|t=2020. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32459190|t=2020. Low levels of total and ionized calcium in blood of COVID-19 patients.|pdf=|usr=007}}
| + | |
| − | {{tp|p=32441666|t=2020. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.|pdf=|usr=007}}
| + | |
| − | | + | |
| − | {{tp|p=32213336|t=ä. SARS-CoV-2: virus dynamics and host response |pdf=|usr=}}
| + | |
| − | {{tp|p=32213337|t=ä. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study |pdf=|usr=}}
| + | |
| − | {{tp|p=32344307|t=2020. COVID-19 type III hypersensitivity reaction |pdf=|usr=}}
| + | |
| − | {{tp|p=32344314|t=2020. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents |pdf=|usr=}}
| + | |
| − | | + | |
| − | | + | |
| − | '''some other papers''' | + | |
| − | | + | |
| − | {{tp|p=32215589|t=2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32360743|t=ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32292530|t=2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan|pdf=|usr=}}
| + | |
| − | {{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}}
| + | |
| − | {{tp|p=32348636|t=2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva |pdf=|usr=}}
| + | |
| − | {{tp|p=32297330|t=2020. Reactive lymphocytes in patients with Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32311762|t=2020. SARS-CoV-2: a new aetiology for atypical lymphocytes |pdf=|usr=}}
| + | |
| − | {{ttp|p=32156572|t=2020. Viroporins and inflammasomes: A key to understand virus-induced inflammation |pdf=|usr=}}
| + | |
| − | {{tp|p=32235915|t=ä. COVID-19: a new challenge for human beings |pdf=|usr=}}
| + | |
| − | {{ttp|p=32359201|t=2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |pdf=|usr=}}
| + | |
| − | {{ttp|p=32073157|t=2020. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus?associated illnesses |pdf=|usr=}}
| + | |
| − | {{tp|p=32376309|t=2020. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32132669|t=ä. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV |pdf=|usr=}}
| + | |
| − | {{tp|p=32388390|t=2020. The powerful immune system against powerful COVID-19: A hypothesis |pdf=|usr=}}
| + | |
| − | {{tp|p=32372807|t=2020. The fever paradox |pdf=|usr=}}
| + | |
| − | {{tp|p=32372779|t=2020. Do you become immune once you have been infected?|pdf=|usr=}}
| + | |
